SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting
April 24 2024 - 10:00AM
Business Wire
SOTIO Biotech, a clinical-stage immuno-oncology
company owned by PPF Group, today announced it will present a
Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030
at the 2024 American Society of Clinical Oncology (ASCO) Annual
Meeting taking place May 31 – June 4, 2024, in Chicago, IL.
BOXR1030 is a next-generation GPC3-targeted CAR T-cell therapy
enhanced with a transgene encoding GOT2, a critical enzyme involved
in cellular metabolism. Preclinical studies of BOXR1030 have
demonstrated its superior activity compared to standard CAR T-cell
therapies. It is the most advanced therapeutic candidate from
SOTIO’s BOXR platform of enhanced cell therapies for the treatment
of solid tumors.
The DUET-01 clinical trial is a first-in-human, open-label,
multicenter, dose escalation study to assess and determine the
recommended Phase 2 dose of BOXR1030 in patients with GPC3 positive
advanced solid tumors. The trial will enroll up to 98 patients with
advanced, unresectable hepatocellular carcinoma, squamous cell lung
cancer, myxoid/round cell liposarcoma, and Merkel cell
carcinoma.
Poster details are as follows:
Title: “DUET-01: A first-in-human, phase 1/2 study of
BOXR1030 in patients with advanced glypican-3-positive solid
tumors” Abstract Number: TPS2681 Session:
Developmental Therapeutics — Immunotherapy Date & Time:
June 1, 2024, 9:00 a.m. – 12:00 p.m. CDT
Presentation materials will be available after presentations
conclude here.
About SOTIO Biotech
SOTIO Biotech (SOTIO) is shaping the future of cancer
immunotherapies by translating compelling science into patient
benefit. The SOTIO pipeline includes SOT102, a next-generation
Claudin-18.2-targeted antibody-drug conjugate which entered the
clinic in 2022; BOXR1030, a metabolically-enhanced CAR-T cell
therapy targeting GPC3-expressing tumors as well as other molecules
approaching clinical stage such as SOT201, our next-generation
PD-1-inhibiting immunocytokine. SOTIO is a member of the PPF Group.
For more information, please visit the company’s website at
www.sotio.com.
SOTIO is a registered trademark of SOTIO Biotech a.s. in
selected countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240424541327/en/
Company contact: Richard Kapsa Head of
Communication T: (+420) 224 174 448 M: (+420) 603 280
971 kapsa@sotio.com
Media contact: Lisa Raffensperger Ten Bridge
Communications M: +1 (617) 903-8783
lisa@tenbridgecommunications.com